株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

局所麻酔薬の世界市場:麻酔薬の種類および用途別分析 - 成長、動向および予測

Local Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 391453
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.69円で換算しております。
局所麻酔薬の世界市場:麻酔薬の種類および用途別分析 - 成長、動向および予測 Local Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 120 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

世界の局所麻酔薬市場は、2017年に60億2000万米ドルに達すると推定されています。世界の局所麻酔薬市場は、2018年から2023年の予測期間中に3.9%のCAGRで成長する見通しです。北米は、プロポフォールの需要の増大により、市場を支配しています。

当レポートでは、世界の局所麻酔薬市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入者の脅威
    • 代替製品とサービスの脅威
    • 業界内の競争優位

第6章 成長要因、阻害要因、機会、課題の分析(DROC)

  • 市場の成長要因
    • 外科医の増加
    • 麻酔薬の新しい承認
    • 美容整形手術の増加
  • 市場の阻害要因
    • 麻酔薬の副作用の危険性
    • 政府別規制上の問題
  • 機会
  • 主な課題
    • 市場セグメンテーション
    • その他の局所麻酔

第7章 地域別セグメンテーション

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ地域
  • 南米

第8章 競合情勢

  • M&A分析
  • 合意、協業および提携
  • 新製品の発売

第9章 企業プロファイル

  • BAXTER
  • MYLAN
  • ABBOTT
  • ASTRAZENECA
  • TEVA PHARMACEUTICALS
  • PFIZER
  • FRESENIUS SE & CO
  • HIKMA PHARMACEUTICALS PLC

第10章 市場の将来展望

目次
Product Code: 46482

Anesthesia is one of the most essential components for any surgical procedure. It induces temporary unconsciousness and loss of protective reflexes. According to the Centers for Disease Control and Prevention (CDC), more than 51 million inpatient surgeries and 53 million outpatient surgeries were performed in the United States in 2017, with the cardiology, surgical, and obstetrical procedures being the most common ones. In Europe, a greater number of surgeries are being performed for cases of cataract, tonsillectomy, colonoscopy, caesarean sections, and hip replacements. In addition, a number of procedures, such as cochlear implantation, laparoscopic colectomy, laparoscopic hysterectomy, secondary hip replacement, and knee replacement, have become more frequent in the recent years. Hence, the overall increase in the number of surgeries performed has a strong impact on the anesthetic drug market, as these drugs are used in all surgical procedures to reduce pain during surgery.

Key Market Trends

Bupivacaine is Expected to Register a Significant Growth in the Forecast Years

Based on drug type, it is segmented into bupivacaine, lidocaine, benzocaine, ropivacaine, prilocaine, chloroprocaine, and other local anesthetics. Bupivacaine is a local anesthetic drug that has been used in various surgical procedures. This is helpful in blocking the nerve impulses that send pain signals to the brain. As per the Royal College of Surgeons, in England (U.K), there were around 4.7 million surgical admissions in 2013/14. There has been a 27% increase in the number of admissions for surgical procedures between 2003-2004 and 2013-14. The most common surgical procedures are hernia repairs, hip replacement, knee replacement, gall bladder removal, and tonsillectomies. Bupivacaine is widely used as local anesthesia, due to its efficacy in numbing certain organ. Hence, the rising number of surgeries leads to high demand for local anesthesia drugs and is expected to propel the growth of the market.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the local anesthesia drugs market and is expected to continue its stronghold for a few more years. The US anesthesia market is the largest regional market in the world. The market is mainly driven by factors, such as the increasing number of surgeries, rising aging population with increasing chronic conditions and advancements in anesthesia technologies. Due to the rising scope of local anesthesia in the market, key players are taking efforts to come up with novel and innovative drugs, thus fueling market growth.

Competitive Landscape

The Local Anesthesia Drugs market is competitive and many of the global players are into the market. Companies are focusing on major collaborations, mergers, and acquisitions in order to enhance their market share. Market players are also focusing on R&D to improve product quality and minimize manufacturing costs, developing novel products to improve patient compliance and safety. Some of the key developments in the market are, in August 2017: Akovaz (Ephedrine Sulfate) injection manufactured by Sandoz Inc. for the treatment of clinically important hypotension got approval of FDA and in July: 2017: Septocaine a local, infiltrative or conductive anesthesia, which is used in dental procedures developed by Hansamed Inc., got FDA approval.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Surgeries
    • 4.2.2 New Approval of Anesthetic Drugs
    • 4.2.3 Growing Use of Local Anesthetic in Post-operative Pain
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Anesthetic Drugs
    • 4.3.2 Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 Bupivacaine
    • 5.1.2 Lidocaine
    • 5.1.3 Benzocaine
    • 5.1.4 Ropivacaine
    • 5.1.5 Prilocaine
    • 5.1.6 Chloroprocaine
    • 5.1.7 Others
  • 5.2 By Mode of Administration
    • 5.2.1 Injectable
    • 5.2.2 Surface Anesthetic
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Fresenius SE & Co. KGaA
    • 6.1.3 Glenmark Pharmaceutical Inc.
    • 6.1.4 Mylan N.V.
    • 6.1.5 Pacira Pharmaceuticals, Inc.
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Septodont
    • 6.1.8 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS